Association of platelet‐monocyte aggregates with platelet activation, systemic inflammation, and myocardial injury in patients with non‐st elevation acute coronary syndromes
Open Access
- 29 January 2007
- journal article
- research article
- Published by Wiley in Clinical Cardiology
- Vol. 30 (1), 26-31
- https://doi.org/10.1002/clc.2
Abstract
Background Platelet-monocyte aggregates (PMA) and C-reactive protein (CRP) are increased in unstable coronary disease. The interrelation of PMA with platelet activation, systemic inflammation, and their association with markers of myocardial injury has not been studied extensively. Hypothesis The study was undertaken to evaluate the association of CRP, PMA, and cardiac troponin I (cTnI) in patients admitted with non-ST elevation acute coronary syndromes (NSTE-ACS). Methods In all, 69 consecutive patients with NSTE-ACS, 58 patients with stable angina pectoris (SAP), and 46 control patients without coronary artery disease were selected; PMA, sP-selectin, sCD40L inter leukin, (IL)-6, CRP, and cTnI concentrations were measured in these patients at the time of admission. Patients with NSTE-ACS were classified into two groups: those with troponin normal (cTnI < 0.06 ng/ml) and those with troponin elevation (cTnI ≥ 0.06 ng/ml). Their risk for clinical in-hospital cardiac events (death and nonfatal myocardial infarction) was analyzed. Results Compared with SAP and control, patients with NSTE-ACS exhibited higher levels of PMA, sP-selectin, sCD40L, IL-6, and CRP. All these parameters were found to be higher (p < 0.001 ) in patients with troponin elevation than in those with normal troponin. There was a significant relationship between PMA and CRP (r =0.628, p < 0.001) and cTnI (r = 0.557, p < 0.001) in patients with NSTE-ACS. Logistic analysis further demonstrated that the presence of elevated PMA, CRP, and cTnI levels each confers and increases risk of future cardiac events. Conclusions Levels of PMA and CRP were significantly increased in patients with NSTE-ACS, especially in those with troponin elevation. This increase is strongly related to the risk of in-hospital cardiac events. A panel of PMA, CRP, and cTnI may provide important information additional to current laboratory data for the treatment of NSTE-ACS. CopyrightKeywords
This publication has 19 references indexed in Scilit:
- Platelet-leukocyte aggregates and derived microparticles in inflammation, vascular remodelling and thrombosisFrontiers in Bioscience-Landmark, 2006
- Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III GuidelinesCirculation, 2004
- C-Reactive Protein: Risk Marker or Mediator in Atherothrombosis?Hypertension, 2004
- Prospective evaluation of the relationship between platelet–leukocyte conjugate formation and recurrent myocardial ischemia in patients with acute coronary syndromesPlatelets, 2004
- Role of P-selectin and PSGL-1 in coagulation and thrombosisThrombosis and Haemostasis, 2004
- Evaluation of the AccuTnI Cardiac Troponin I Assay for Risk Assessment in Acute Coronary SyndromesClinical Chemistry, 2003
- Inflammation and AtherosclerosisCirculation, 2002
- Markers of Myocardial Damage and Inflammation in Relation to Long-Term Mortality in Unstable Coronary Artery DiseaseThe New England Journal of Medicine, 2000
- Myocardial infarction redefined—a consensus document of The Joint European Society of Cardiology/American College of Cardiology committee for the redefinition of myocardial infarction: The Joint European Society of Cardiology/ American College of Cardiology CommitteeJournal of the American College of Cardiology, 2000
- Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysisJournal of the American College of Cardiology, 2000